BioKePharm And Marcucci Merge
US-based company BioKePharm is merging with Italian company Gruppo Marcucci, which is a European leader in biological products, to form an alliance in the biologicals sector.
The new company will retain the name BioKePharm and has aggressive plans for rapid expansion into the USA and other major and emerging international markets, according to Ralph Galustian, the founder of BioKePharm, and Guelfo Marcucci, the founder and chairman of Marcucci. The new company aims to be among the top three leading companies in the industry by the year 2000.
BioKePharm intends to expand production by 100% over the next three years. Estimated company sales for the current year are $165 million. The firm's product line includes a wide range of plasma-derived products.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze